Next Article in Journal
Structure and Functional Analysis of Promoters from Two Liver Isoforms of CPT I in Grass Carp Ctenopharyngodon idella
Next Article in Special Issue
Activation of TREK-1, but Not TREK-2, Channel by Mood Stabilizers
Previous Article in Journal
Regulation of the Rhythmic Emission of Plant Volatiles by the Circadian Clock
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(11), 2406; https://doi.org/10.3390/ijms18112406

Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression

1
Department of Psychiatry, Cancer Center, Dongnam Institute of Radiological & Medical Sciences, Busan 46033, Korea
2
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea
3
Department of Psychiatry, School of Medicine, Jeju National University, Jeju 63241, Korea
*
Author to whom correspondence should be addressed.
Received: 29 September 2017 / Revised: 6 November 2017 / Accepted: 9 November 2017 / Published: 13 November 2017
View Full-Text   |   Download PDF [375 KB, uploaded 14 November 2017]   |  

Abstract

The concept of the bipolar-spectrum and of mixed features being a bridge between major depressive disorders and bipolar disorders (BDs) has become increasingly important in mood-disorder diagnoses. Under these circumstances, antidepressants (ADs) and mood stabilizers (MSs) should be used with caution in the treatment of major depressive episodes (MDEs) and to obtain long-term stability in BDs. Before treating MDEs, screening tools, specific symptom evaluation and medical history should be used to distinguish between bipolarity and mixed features in patients for whom AD monotherapy may present a risk. In these patients, a combination of ADs plus MSs or atypical antipsychotics is recommended, rather than AD monotherapy. Studies evaluating MSs for bipolar depression suggest that lamotrigine is the most reliable treatment and lithium has modest effects; there is a lack of clear evidence regarding the efficacy of valproate and carbamazepine. Recently, significant progress has been made with respect to the pathophysiology of mood disorders and the application of potential biomarkers. There is an opportunity to study novel drug mechanisms through the rediscovery of fast-acting drugs such as ketamine. It is anticipated that future research developments will involve the discovery of potential targets for new drugs and their application to personalized treatments. View Full-Text
Keywords: antidepressant; mood-stabilizer; lithium; depression; mixed features; major depressive episode; bipolar disorder antidepressant; mood-stabilizer; lithium; depression; mixed features; major depressive episode; bipolar disorder
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Shim, I.H.; Woo, Y.S.; Kim, M.-D.; Bahk, W.-M. Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression. Int. J. Mol. Sci. 2017, 18, 2406.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top